



Resources from the Societies



- Patient Information at OrthoInfo.org
- Technology Overview
- Participation in ASTM and ISO



- Member education



- ORS.org – Clinical Research symposia and forums



- Patient Information
- Educational programs

Presenting on behalf of AAOS, AAHKS, ORS and the Hip Society

Paul Manner, MD – Opening remarks,
history of metal on metal with current
clinical outcomes, results of the AAOS
Technology Overview

Markus Wimmer, PhD – preclinical
testing, implant retrieval analysis, and
tribology/tribocorrosion

Young-Min Kwon, MD, PhD – local and
systemic effects, management strategies,
and algorithm

The safety of every orthopaedic patient is always our number one concern. We welcome the publication of updated evidence and we will continue to work with the FDA to provide further advice as new information and evidence becomes available.

*FDA Orthopaedic Rehabilitation Devices Panel
Medical Devices Advisory Committee Meeting
Wednesday June 27th 2012*

**MODERN METAL-ON-
METAL HIP IMPLANTS: A
CLINICIAN'S
PERSPECTIVE AND A
TECHNOLOGY
OVERVIEW**

Paul Manner, MD, FRCSC(C)

Associate Professor

Department of Orthopaedics and Sports Medicine

University of Washington

Seattle, WA

Disclosure

- No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this testimony.

Clinician's Dilemma

“Objectives must be reasonable. Neither surgeon nor engineers can ever make an artificial hip-joint that will last thirty years and at some time in this period enable the patient to play football.”

- John Charnley



Clinical Goals for a Total Joint

Primary goal

Relieve pain

Restore function

Secondary goals

Simple

Be good to soft tissue

Manufacturability


Safety

Durability

Fixable

Cheap

Defining the current standard and clinical expectation



- What did we expect in the 1960s?
 - Initially restricted to patients >65 yo
 - Severe RA or OA
 - Occasional middle-aged patient with bilateral disease

What do we expect now?

AAHKS members allow:

Walking/hiking	98%
Biking	80%
Skiing	21%
	56% with experience
Martial arts	9%
Running	6%
Contact sports	2%

Klein et al, J Arthroplasty 2007


What do patients expect?



“I want to do what I was doing before my hip hurt!”

But reality intrudes....

“...the principal culprit of long-term implant failures has been identified as the ultra high molecular weight polyethylene (UHMWPE) wear debris generated at the articulating surface of the polymer component”



AAOS Monograph 2001

Two main approaches to wear reduction

■ Decrease opportunities for wear

- ◆ Increase contact area with more conforming surfaces by prosthesis design (macro)
- ◆ Avoid technical errors/malalignment (macro)
- ◆ Increase contact area by tighter tolerances in manufacture (micro)
- ◆ Amelioration/elimination of backside wear (nano)


■ Create better bearing surface

- ◆ Change polyethylene
- ◆ Eliminate polyethylene

Poly-II


- Withdrawn from market, after reports of catastrophic failure, 7 years after introduction

Wright et al JBJS 1988



Heat-pressed Polyethylene

- High incidence of delamination
- Surface layer separated from insert by clear line of demarcation 250-580 μm below surface
- 17/33 retrieval specimens showed delamination at 4 years




Bloebaum et al Clin Orthop 1991

Hylamer at 10 years

- “...number of pelvic osteolytic lesions and their size detected on plain radiographs were significantly greater for Hylamer liners”

Huddleston et al 2010



Patients are different....




McKee-Farrar

- Poor stem geometry
 - ◆ Sharp angles
 - ◆ Not enough offset
- Crude manufacture
- Crude technique
- 28-year implant survivorship of 74%



Brown et al 2002

Long-term results with first generation implants



Jacobsson et al 1996

Conclusions in 2000

- Not all patients are the same
- Not all plastic bearings are created equal
- What are clinician's options?
- Hard-on-hard bearing looks attractive...

Background to Technology Review

- MoM marketed in US prior to 1976
- DePuy ASR approved in US in 2005
- Zimmer Durom, Smith and Nephew BHR approved in 2006
- Durom, ASR soon withdrawn

Background to Technology Review

- Feb 2011: FDA issues public communication about metal-on-metal
- May 2011: FDA orders manufacturers to conduct post-market surveillance
- June 2011: AAOS creates Technology Overview group

AAOS Technology Review

- Clinicians and researchers
- Relevant questions chosen
- Prepared using systematic review methodology
- Summarizes findings of studies published as of July 15, 2011 on modern metal-on-metal hip implants

- **Question #1: What are the clinical outcomes in patients with metal-on-metal hip replacements in comparison with other bearing surface combinations?**

- **Question #2: What are the patient, implant, and surgical factors that best predict successful/unsuccessful outcomes of metal-on-metal hip replacement?**

- **Question #3: What is the prevalence of adverse clinical problems from metal-on-metal hip replacement compared to other bearing surface combinations?**

Outcomes considered

- Patient focused: Harris Hip Score, WOMAC, etc
- Revision rates
- Serum ion as potential surrogate marker
- Imaging

Systematic review

- Frame key question(s)
- Rules for inclusion
- Comprehensive literature review
- Evaluation of quality of studies

Systematic review rules

- Criteria established prior to literature search
- Highest possible levels of evidence
- Published, peer-reviewed only
- Contemporary implants only

Literature quality

- Searches identified 3038 hip replacement citations and data from 8 joint registries that were potentially relevant
- 19 articles and 2 joint registry reports met inclusion criteria

1: Clinical outcomes

- Registry data (UK-Wales, Australia)
- Metal-on-metal HRA and THA have higher risk of revision
- No clinical superiority for any particular bearing surface
- Not clear if particular patients benefit

2: Predictive factors

- Larger femoral head components in MoM THA have higher revision rates
- Increased age associated with increased revision risks MoM THA
- HRA patients in all age groups, except males <55 years of age, at increased revision risk

2. Predictive factors

- Head size and risk of revision for HRA inversely related (opposite of THA)
- Analysis difficult
- Conclusions should be made cautiously

3. Prevalence in MoM versus others

- Limited data exists comparing prevalence of adverse clinical problems with MoM versus other bearing surfaces
- High sensitivity to component position
- Clinical significance of elevated serum metal ion concentrations remains unknown

Serum metal ions

- All MoM hip implants wear and cause metal ion release
- Believed to cause soft tissue reactions in periprosthetic space
- Data comparing metal-on-metal THA/HRA to other bearing surfaces are sparse and drawing conclusions is difficult

Registry data valuable, but...

■ Pro

- ◆ Large patient numbers
- ◆ Quick identification of problematic implants

■ Con

- ◆ “Lumping” versus “splitting”
- ◆ Complexity of needed data makes collection/compliance difficult

Increasing number of positive reports

- Reports of small diameter MOM bearings with survival rates of $\geq 95\%$ at 10 years
 - ◆ Gröbl et al. JOR 2007 25(7):841-8.
 - ◆ Delaunay et al. 2008 CORR 466(2):340-6
 - ◆ Girard et al. 2010 JBJS-A 92(14):2419-26
 - ◆ Hwang et al. 2011 JOA 26(8):1481-7
 - ◆ Nikolaou et al. 2011 Bull NYU Hosp 69:S77-83
 - ◆ Migaud et al. 2011 JBJS-A 93(Suppl 2):137-42
 - ◆ Randelli et al. 2012 JOA 27(2):186-92

MoM vs CoP in patients < 50 yrs

- Comparison between:
 - ◆ 39 MoM hips w. \varnothing 28 mm head
AlloClassic system; patients <50 yrs
 - ◆ 39 ZrO₂ - UHMWPE hips
ABG stem / Harris-Galante cup; patients <50 yrs
- Matched group for age, diagnosis, activity and pre-operative Harris hip score


H. Migaud et al, JBJS, 93A, Suppl 2, 2011, p. 137

MoM vs CoP in patients < 50 yrs


	MoM small head	ZrO ₂ - UHMWPE
Min follow-up	144 months	110 months
Harris hip score	92.8	91.2
Osteolysis	1 (3%)	18 (46%)
Revision	0 (0%)	13 (33%)
Survival rate	100%	70%

H. Migaud et al, JBJS, 93A, Suppl 2, 2011, p. 137

Are these the same?





Survival Curve with 95% CL



2011 Australian Registry

■ >32mm heads

■ ≤32mm heads



2012 AAHKS Survey

- 1363 active members
- 598 responses (44%)

BEARING OF CHOICE FOR MAJORITY OF PATIENTS

- | | |
|-------------------|-------|
| ■ Metal-on-poly | 84.5% |
| ■ Ceramic-on-poly | 14.1% |
| ■ Metal-on-metal | 1.4% |

2012 AAHKS Survey

- 1363 active members
- 598 responses (44%)

USE OF METAL-METAL BEARINGS (CHANGE 2009-2012)

- | | |
|-----------------------------|-------|
| ■ Discontinued / never used | 69.2% |
| ■ Decreased | 23.9% |
| ■ Unchanged | 4.6% |

Conclusions in 2012

- As with polyethylene, some implants may be heroes, and some may be goats
- Adverse local tissue reaction (ALTR) is response in a given patient to a given material used in a given design
- Blanket approval/condemnation not an adequate answer

Conclusions in 2012

- Can't determine whether one particular type of patient fares better than others
- Need to account for effects of all patient and device characteristics of interest
- Analyze interactions between relevant variables
- To date, such analyses have not been conducted

Thank you

*FDA Orthopaedic Rehabilitation Devices Panel
Medical Devices Advisory Committee Meeting
Wednesday June 27th 2012*

TRIBOLOGY AND PRE-CLINICAL TESTING IN MOM HIP JOINTS

Markus A. Wimmer, PhD

Associate Professor

Department of Orthopedic Surgery

Rush University Medical Center


Chicago, IL

Disclosure

- No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this testimony.
- Unpaid consultant for Endolab in Germany.


History of Metal-on-Metal

- 1930's: Wiles tries 304L steel for hip prosthesis
MGH dentists use Co-base alloys w. success
- 1950's Co-base alloys introduced to THR
- 1960's: McKee-Farrar choose CoCrMo alloy based on Stanmore hip
- 1980's: New generation of MoM bearings with 28 mm head size (which function well till today)
- Late 1990's: McMinn popularizes hip resurfacing
- 2000's: Large head sizes (>36 mm) for THR to (1) avoid dislocation and (2) improve tribology




Influence of Head Radii on Wear

Smith, Dowson et al. Proc Instn Mech Engrs Vol 215 Part H, 2001




Influence of Head Radii on Wear

Dowson et al. J Arthrop 19(8), Suppl.3:124-130, 2004




Lubrication Theory



Hamrock-Dowson equation (1978)

Medley, J.B. (2008) Tribology of bearing materials. Chapter 4 in *Hip Resurfacing: Principles, Indications, Technique and Results*, by H. C. Amstutz, Saunders Elsevier, 33-44.

Lubrication Theory



Dry contact




Boundary Lubrication



Mixed lubrication




Fluid film lubrication



Medley, J.B. (2008) Tribology of bearing materials. Chapter 4 in *Hip Resurfacing: Principles, Indications, Technique and Results*, by H. C. Amstutz, Saunders Elsevier, 33-44.


Film thickness (Hamrock-Dowson)

- Input: Load $F=3.000$ N; fluid viscosity $\eta=0.005$ Pa·s



Influence of Radius on Fluid Film


- Jin et al. Analysis of mixed lubrication mechanism in metal-on-metal THR. Proc Inst Mech Eng H. 21685, 2002



Prediction of the λ ratio as a function of the femoral head radius for the nominal conditions (Table 1), a decrease in the surface roughness to $0.01 \mu\text{m}$ and an increase in the radial clearance to $80 \mu\text{m}$

Influence of Clearance on Fluid Film


- Jin et al. Analysis of mixed lubrication mechanism in metal-on-metal THR. Proc Inst Mech Eng H. 21685, 2002




Prediction of minimum film thickness for metal-on-metal hip joint replacements for different radial clearances ($w = 2.5$ kN, $R_1 = 14$ mm, $E_1 = 230$ GPa, $E_2 = 230$ GPa, $\nu_1 = 0.3$, $\nu_2 = 0.3$, $u = 0.015$ m/s, $\eta = 0.005$ Pa s)

Current wear testing procedures

- Input defined in ISO 14242-1 and ISO 14242-3
 - ◆ 5 million cycles at $\sim 1\text{Hz}$
 - ◆ Lubricant: bovine serum (30g/L protein)



ISO Hip Simulator Wear Rates





Over 100-fold (!) difference in wear of MoM bearings

How can we make pre-clinical testing more predictive ?

=> Include adverse conditions observed in clinical service

1) Malpositioning

Steep inclination=> small 'coverage angle'¹



¹ De Haan et al., JBJS-Br 90B:1291, 2008


Wear and inclination (retrieval study)

		Wear Volume [mm ³ / year]		Inclination [°]	
		Head	Cup	Head	Cup
No Rimloading					
n		129	10	108	8
mean		0.24	0.66	47.7	49.0
StD		0.53	1.54	6.9	4.0
Min		0.00	0.00	30.0	42.0
Max		3.04	4.89	65.3	54.0
Rimloading					
n		23	15	22	10
mean		7.14	14.41	55.5	58.0
StD		5.20	16.33	10.3	10.9
Min		1.06	0.17	40.0	45.0
Max		22.38	59.83	75.0	75.0
p=		<0.001	0.015	<0.001	0.043

Influence of design on malpositioning


Fully hemispherical
bearing surface

Articulation angle: 180°





Truncated bearing
surface

Articulation angle: 165°



2) Lack of fluid film

- Predominantly mixed lubrication during many occasions of daily living
=> requires tribofilm at the surface to avoid metal/metal contact




Wimmer, Fischer et al., Wear 2003

Tribofilm cross-section

carbonaceous composite with metallic, ceramic nano-crystals



Pourzal et al. J Mech Behavior Biomed Mat 2009



Tribofilm cross-section

carbonaceous composite with metallic, ceramic nano-crystals and graphitic material

Liao et al. Science 334:1687, 2011





Beneficial role of tribofilm

- Mechanical protection of the underlying metal surface, similar to low-friction, anti-wear additives of high performance lubricants
- Graphitic sliding
CoF < 0.05
- Reduced friction
=> reduced wear
- Also: improves
(tribo-)corrosion
behavior


Mathew et al, ORS 36:384,
2011



3) Synergistic interaction of wear and corrosion



Comparison between synergistic component at E_{corr} and E_{anodic}




Synergistic interaction at E_{anodic} is so high that pure tribology and corrosion components are negligible.


At E_{corr} interplay of the wear and corrosion mechanisms become the driving mechanisms.

Tribocorrosion

- is an irreversible transformation of material in tribological contact caused by simultaneous **physico-chemical and mechanical** surface interactions.



Tribocorrosion system (principle)



Tribocorrosion system


Contact zone

Tribology: Friction coefficients

Corrosion: Current or potential changes


Formation and retention of tribofilm

- Tribofilm only generated and retained in a certain range of loads (~50-80 MPa)



- LC-CoCrMo
- Bovine serum
- Frequency: 1 Hz
- Cycles: 1,800



Normalized electrical film resistance after sliding



Wimmer et al,
ORS 37:1036,
2012

4) High MoM friction



- Increased friction (particularly, after periods of rest)
- Increased lever-arm in large head MoM



Nassutt et al.
CORR 407:127,
2003

Taper junction as another wear source



- Not just an MoM problem (Kop et al, J Arthrop 24:1019, 2009)
- High torque due to large friction and head size



Langton et al,
BJR, 1:56, 2012

Taper junction as another wear source


- Taper wear increases with head size



Langton et al,
BJR, 1:56, 2012

5) Variable Metallurgy



- Role of hard phases on wear?



Fischer et al.,
MoM Symp 2012
ASTM STP 1560


5) Variable Metallurgy

■ Role of hard phases on wear?



Fischer et al.,
MoM Symp 2012
ASTM STP 1560

5) Variable Metallurgy



Fischer et al.,
MoM Symp 2012
ASTM STP 1560

6) Other adverse conditions

■ Mechanical

- ◆ Micro-separation
- ◆ Third bodies (intrinsic / extrinsic)

■ Chemical

- ◆ Creation of local cell (potential shift)
- ◆ pH shift away from neutral
- ◆ Bacterial infection (LPS presence)

■ Combined mechanical /chemical attack

- ◆ Tribo-corrosion
- ◆ Stress corrosion

Current activities & research needs identified by ASTM

- Standard in development for bearing surface wear in MOM bearings
- Differentiate between types of ALTRs (e.g., hypersensitivity, ALVALs, metal toxicity, pseudotumors)
- Standardize particle characterization for MOM bearings

Current activities & research needs identified by ASTM

- Standard for taper wear and measurement
- Standard for orthopedic tapers
- Algorithmic approach for synthesis of clinical data (x-rays, MRI), wear measurement (CMM, OOR), surface analysis techniques (SEM), histological analysis and fluid characterization

Current activities & research needs identified by ASTM

- Standardize hypersensitivity testing
- Standardize metal ion testing in body fluids
- Adverse preclinical testing
- Synovial fluid characterization
- Preserve history of retrieval analysis

Thank you

*FDA Orthopaedic Rehabilitation Devices Panel
Medical Devices Advisory Committee Meeting
Wednesday June 27th 2012*

**BIOLOGICAL
REACTIONS TO
METAL-ON-METAL HIP
IMPLANTS**

Young-Min Kwon MD, PhD

Department of Orthopaedic Surgery

Massachusetts General Hospital

Assistant Professor

Harvard Medical School

Disclosure

- No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this testimony.

Biological Reactions to MoM

■ Systemic

- ◆ Chromosomal/
Carcinogenesis
- ◆ Teratogenecity
- ◆ ‘Cobaltism’

■ Local

- ◆ Osteolysis
- ◆ Hypersensitivity
- ◆ Pseudotumours

Systemic Adverse MoM Reactions

- Metal ions lead to the generation of free radicals
- Free radicals induce DNA cross-links
- Chromosome translocations and aneuploidy in peripheral blood lymphocytes at 6, 12 and 24 months post surgery (*Ladon et al. JOA 2004*)
- Permanent modification of genetic material may represent the first step involved in carcinogenesis.

Carcinogenesis

- The carcinogenic potential of cobalt and chromium wear particles have been demonstrated in animal models (*Heath et al. Lancet 1971*)
- Currently available data on risk of cancer does **not** support a causal link (*Smith et al. BMJ 2012; Silva et al. CORR 2005; Tharani et al. JBJS A 2001*)
- These studies limited by a small number of patients and short follow up period.

Teratogenicity

- MoM performed in young patients, including females of child bearing age, concern that mutagenic or teratogenic effects
- **Cord blood levels** of cobalt and chromium were **60%** of the mean maternal blood levels in patients with hip resurfacing (*Ziaee et al. JBJS B 2007*)
- Placenta may exert a modulatory effect on the rate of metal

‘Cobaltism’



- Series of case reports describing temporal association of metal toxicity (**Tower JBJS A 2010; Mao *et al.* MJA 2011**)
- Neurologic and cardiac dysfunction
- Case reports with ASR MoM THA
- Cobalt serum level 35-112 ug/L
- Optic atrophy and cardiac dysfunction

Local Adverse MoM Reactions

- Osteolysis (*Park et al. JBJS 2005*)
- Adverse Soft Tissue Reactions
 - ◆ ‘Hypersensitivity’ (ALVAL)
 - ◆ ‘Pseudotumours’
- **How Big is the Problem?**
- Is it Metal Hypersensitivity?
- Is there Increased Metal Debris?


Local Abnormal Soft Tissue Reactions

- Observed in Patients following MoM resurfacing & MoM THA
- Described as “Pseudotumour”
- Many other names:
 - ◆ Metallosis
 - ◆ A.L.V.A.L
 - ◆ A.R.M.D
 - ◆ A.L.T.R



Histology


- Lymphocyte infiltration
 - Similar to A.L.V.A.L (Willert JBJS 2005)
- But **extensive necrosis** with collection of dead macrophages with metal wear debris (essential feature)



Mabilleau, Kwon *et al.* Acta Orthop 2008

Histology

- Spectrum of histological features (**Campbell *et al.* CORR 2010**)
 - ◆ Scoring system
 - ◆ Synovial lining; cell types; tissue organization
 - ◆ Metal allergy *vs.* necrosis




How Big Is The Problem?

- Incidence varies between centers and different end-points
- Hard-Endpoint (Revision for Pseudotumour)
- Overall incidence 0.1-3%
- Some centers higher
- Designer surgeon centers lower

'Asymptomatic' Pseudotumours

- Some patients with bilateral MoMHRA presented with symptom in one hip only
- However, pseudotumours found in both **symptomatic** and **asymptomatic** resurfaced hips

'Asymptomatic' Pseudotumours



'Asymptomatic' Pseudotumours

Kwon et al. JoA 2011

- N=201 consecutive MoMHRA
- Asymptomatic
- 'Screened' using US/MRI
- 4% Prevalence
- Size ranges 2×1×2 cm to 8×7×8 cm

'Asymptomatic' Pseudotumours


- *Williams et al. JBJS Am 2011*
 - ◆ N=73 Asymptomatic 'Screened' using **US**
 - ◆ Prevalence 27% MoM THA; 14% MoMHRA
- *Wynn-Jones et al. Acta Orthop 2011*
 - ◆ N=77 Asymptomatic ASR 'Screened' using **MRI**
 - ◆ Prevalence 31%
- *Bosker et al. Paper #303, AAOS 2012*
 - ◆ Prevalence 31% following CT screening
 - ◆ No difference in clinical outcome scores

How Big Is The Problem?

- The precise prevalence is unknown
- Appreciable number of ‘asymptomatic’ or sub-clinical pseudotumors
- US/MRI scans required to detect or ‘screen’ for pseudotumors
- Concern that ‘asymptomatic’ pseudotumors increase the incidence of symptomatic pseudotumors


Is It Hypersensitivity Reaction?

- Lymphocyte infiltration
 - **Similar to A.L.V.A.L**
(Willert *et al.* JBJS A 2005)
- **ALVAL:**
 - ◆ Type IV delayed hypersensitivity reaction
 - ◆ Driven by T-lymphocytes
 - ◆ Sensitized due to continuous exposure to metal ions



Testing for Hypersensitivity

- Traditional *in vivo* Skin Patch Testing
- Limitations
 - ◆ Dermal vs. deep tissue
 - ◆ Duration of exposure
 - ◆ Falsely negative in immunosuppressed, tolerance
 - ◆ Sensitisation



Lymphocyte Transformation Tests

- Lymphocyte proliferation response to a challenging agent
- T lymphocyte responsible for activation and memory in type IV hypersensitivity (ALVAL)
- Measures sensitisation
 - ◆ Previous exposure
 - ◆ Immune memory and response

Lymphocyte Transformation Tests

- Lymphocyte proliferation response to a challenging agent
- **T lymphocyte** responsible for activation and memory in type IV hypersensitivity (**ALVAL**)
- Measures sensitisation
 - ◆ Previous exposure
 - ◆ Immune memory and response
- **? Pre-operative screening test**


Lymphocyte Transformation Tests

Patient Group	Number	Mean Age (years)	Mean Follow-up (months)
Pseudotumour	10 (1M:9F)	56 (45-62)	65 (19-79)
Non-Pseudotumour	60 (30M:30F)	55 (40-69)	61 (13-88)
Control	22 (13M:9F)	55 (50-58)	Pre-operative

Kwon et al. JOR 2010

Lymphocyte Reactivity

- **NO difference** in lymphocyte reactivity to Co or Cr between pseudotumour and non-pseudotumour groups



Kwon et al. JOR 2010

Lymphocyte Reactivity

Langton *et al.* JBJS Br 2010


- Patients with ASR with adverse soft tissue reactions undergoing revision
- **NO** patient with ARMD showed increased lymphocytic reactivity (LTT) to Co or Cr
- One showed a mild reactivity to Ni

Is It Hypersensitivity Reaction?

- Hypersensitivity type IV reactions (**ALVAL**), mediated by lymphocyte reactivity to these metals may play an important role in pathogenesis
- However, **not** the only mechanism
- Further research required before recommending routine use of **LTT** as screening test

Is It Metal Cytotoxicity?


- Histology:
 - ◆ Essential feature of **extensive necrosis** with collection of macrophages
 - ◆ **Metal particle aggregates**



Mabilleau, Kwon *et al.* Acta Orthop 2008

Metal Cytotoxicity



- Cobalt nanoparticles and ions have dose-dependent cytotoxic effects on macrophages *in vitro*
- In the presence of a high level of metal wear debris and prolonged exposure *in vivo*, cytotoxicity of macrophages lead to tissue necrosis



Kwon *et al.* Biomed Materials 2009

SEM/EDX

- Metal particle aggregates within macrophages
- Co and Cr particles





Kwon et al. JoA 2010

Is There Increased Metal Wear Debris?

- Elevated Metal ion levels
- Increased implant wear occurring at MoM articulation

Elevated Serum Metal Ion Levels



Kwon *et al.* JoA 2011

Metal Ion Levels



- Cobalt and Chromium ion levels
 - ◆ Most pseudotumours detected with the levels higher than reported from well-functioning MoMHRA
- Elevated serum metal ion correlated with MoMHRA wear (**De Smet *et al.* JBJS A 2008**)
- ? Pseudotumours due to increased wear

Wear Analysis of Retrieved Implants

	Pseudotumour Group	Non-Pseudotumour Group
Number of implants	8	22
Gender (female: male)	8:0	13:9
Mean Age (years)	52 (range 39 - 65)	54 (range 45 - 70)
Mean Time <i>in vivo</i> (years)	3.6 (range 1.1 – 6.6)	2.3 (range 1.0 – 5.8)
Mean Femoral component size (mm)	47 (range 42 - 50)	49 (range 44 - 54)
Implant Type	BHR (5) Conserve Plus (2) Cormet (1)	BHR (18) Conserve Plus (4)


Kwon et al. JBJS Br 2010

Linear Wear Rate



Kwon *et al.* JBJS Br 2010

Wear Pattern: Edge Loading



- EL observed in all acetabular implants in the pseudotumour group
- EL observed in one implant in the non-pseudotumour group ($p=0.03$)

Kwon *et al.* JBJS Br 2010

Tribocorrosion in MoM THA

Matthies *et al.*

Paper #357, AAOS 2012

Takamura *et al.*


Paper #562, AAOS 2012

Urban *et al.*

Poster #P012, AAOS 2012



Engh *et al.*

Poster #P068, AAOS 2012



- 48% - 100% extreme taper corrosion association with ridges on female taper surface
- Common with ASTR

'Low' Wear Pseudotumours



Glyn-Jones, Roques, Kwon *et al.* JBJS Am 2011

'Low' Wear Pseudotumours

- **Matthies *et al.* CORR 2012**
- **Matthies *et al.* Paper #304, AAOS 2012**
 - ◆ Retrieval study of 105 MoM hips
 - ◆ No significant association between many pseudotumours and component wear rates
 - ◆ Suggesting important patient susceptibility factors

How to Evaluate Painful MoM

■ Systematic Approach

- ◆ Clinical Hx and Physical Exam
- ◆ Radiographs
- ◆ Lab Tests: ESR/CRP/Joint Aspiration
- ◆ Cobalt and Chromium ion levels
- ◆ Cross Sectional Imaging
 - ◆ Ultrasound, MRI

Table. Differential Diagnosis for the Painful MoM Hip Arthroplasty

Extrinsic to the Hip

Spine disease: stenosis, disc herniation, spondylolysis, or spondylolisthesis

Peripheral vascular disease

Complex regional pain syndrome

Psychologic disorder

Hernia (femoral, inguinal)

Peripheral nerve injury (eg, sciatic, femoral, meralgia paresthetica)

Malignancy or metastases

Metabolic bone disease (eg, Paget disease, osteomalacia)

Intrinsic to the Hip

Intracapsular/implant related

Infection

Loosening

Instability/subluxation

Periprosthetic fracture

Adverse soft tissue reaction/hypersensitivity

Extracapsular

Trochanteric bursitis

Iliopsoas tendonitis

Kwon, Jacobs *et al.* JoA 2012

Systematic Evaluation Guidelines

Parameters/Categories

- Implant type (Hip resurfacing, Stemmed MoM femoral head <36mm and ≥36mm, Recalled)
- Symptoms symptomatic vs. asymptomatic
- Follow up
 - ◆ Frequency and duration (? for life of implant)
- Cross-Sectional Imaging
 - ◆ MRI vs. US
 - ◆ Indications
- Metal ions levels
 - ◆ Threshold (? >7ppb)
 - ◆ Indication for repeat testing
- Indications for revision surgery
 - ◆ Imaging abnormal
 - ◆ Metal ions rising

Appendix


Management recommendations for patients with metal-on-metal hip replacement implants

	MoM hip resurfacing (no stem)		Stemmed MoM total hip replacements – femoral head diameter <36mm		Stemmed MoM total hip replacements – femoral head diameter ≥36mm		DePuy ASR™ hip replacements (all types)	
	Symptomatic patients	Asymptomatic patients	Symptomatic patients	Asymptomatic patients	Symptomatic patients	Asymptomatic patients	Symptomatic Patients	Asymptomatic patients
Patient follow-up	Annually for not less than five years	According to local protocols	Annually for not less than five years	According to local protocols	Annually for life of implant	Annually for life of implant	Annually for life of implant	Annually for life of implant
Imaging: MARS MRI or ultrasound	Recommended in all cases	No - unless concern exists for cohort or patient becomes symptomatic	Recommended in all cases	No - unless concern exists for cohort or patient becomes symptomatic	Recommended in all cases	Recommended if blood metal ion levels rising	Recommended in all cases	Recommended in all cases
1st blood metal ion level test	Yes	No - unless concern exists for cohort or patient becomes symptomatic	Yes	No - unless concern exists for cohort or patient becomes symptomatic	Yes	Yes	Yes	Yes
Results of 1st blood metal ion level test	Blood metal ion level >7ppb indicates potential for soft tissue reaction		Blood metal ion level >7ppb indicates potential for soft tissue reaction		Blood metal ion level >7ppb indicates potential for soft tissue reaction	If blood metal ion level >7ppb then second blood test required 3 months later	Blood metal ion level >7ppb indicates potential for soft tissue reaction	If blood metal ion level >7ppb then second blood test required 3 months later
2nd blood metal ion level test	Yes - 3 months after 1 st blood test if result was >7ppb		Yes - 3 months after 1 st blood test if result was >7ppb		Yes - 3 months after 1 st blood test if result was >7ppb	Yes - 3 months after 1 st blood test if result was >7ppb	Yes - 3 months after 1 st blood test if result was >7ppb	Yes - 3 months after 1 st blood test if result was >7ppb
Results of 2nd blood metal ion level test	Blood metal ion level >7ppb indicates potential for soft tissue reaction especially if greater than previously		Blood metal ion level >7ppb indicates potential for soft tissue reaction especially if greater than previously		Blood metal ion level >7ppb indicates potential for soft tissue reaction especially if greater than previously	If blood metal ion levels rising - further investigation required including imaging	Blood metal ion level >7ppb indicates potential for soft tissue reaction especially if greater than previously	Blood metal ion level rising indicates potential for soft tissue reaction
Consider need for revision	If imaging is abnormal and/or blood metal ion levels rising		If imaging is abnormal and/or blood metal ion levels rising		If imaging is abnormal and/or blood metal ion levels rising	If imaging is abnormal and/or blood metal ion levels rising	If imaging is abnormal and/or blood metal ion levels rising	If imaging is abnormal and/or blood metal ion levels rising

Notes and guidance on next page

MHRA Medical Device Alert/2012/0008

MoM Diagnostic Algorithm



Steven J. MacDonald, MD, FRCSC, 2011

Fig. 1. A diagnostic algorithm for evaluation and treatment for patients with MoM hip arthroplasty.

Kwon, Jacobs *et al.* JoA 2012

Systematic Evaluation Algorithm

■ Concerted Initiative

- ◆ AAOS
- ◆ AAHKS
- ◆ Hip Society

■ MoM Task Force

- ◆ Currently working on developing algorithm

Summary

- Histological features and MoM implant failure not been fully established
 - ◆ ALVAL-like features observed in failures from mechanical causes
- Further standardize histological evaluation of periprosthetic tissues
 - ◆ metal allergy *vs.* wear-related necrosis
- Currently, no standardized validated clinical tests to screen or diagnose metal hypersensitivity

Summary

- **Spectrum** of Clinical Presentations & Etiologies
 - Majority Symptomatic
 - ? Minority ‘Asymptomatic’
 - Majority with High-Wearing \pm Corrosion (Elevated Metal Ion Levels)
 - ? Minority with Low-Wearing (‘Low’ Metal Ion Levels)
- **Dose-Dependency vs. Patient Susceptibility (Hypersensitivity)**
- **Complex interplay of Implant, Patient and Surgical factors**

Summary

- Edge-Loading in MoM
 - ◆ Responsible for Localised Excessive Wear
- Low Threshold for Further Evaluation
 - ◆ Metal Ion Levels and MARS MRI
- Evidence-based systematic evaluation guidelines
 - ◆ Continue to develop with updated evidence
- Further Research required to further identify Multi-Factorial Etiology of Local Adverse Tissue Reactions

Thank You

Resources from the Societies



- Patient Information at OrthoInfo.org
- Technology Overview
- Participation in ASTM and ISO



- Member education



- ORS.org – Clinical Research symposia and forums



- Patient Information
- Educational programs

